NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Samson DJ, Ratko TA, Rothenberg BM, et al. Comparative Effectiveness and Safety of Radiotherapy Treatments for Head and Neck Cancer [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2010 May. (Comparative Effectiveness Reviews, No. 20.)
Comparative Effectiveness and Safety of Radiotherapy Treatments for Head and Neck Cancer [Internet].
Show details- Δ
change
- ~
approximately
- 1o
primary
- 2.5D
2 ½ D RT
- 2D
two-dimensional
- 2DRT
2D conventional RT
- 3D
three dimensional
- 3DC
3D conformal RT
- 3DCRT
3D conformal radiotherapy
- ACC
accelerated fractionation
- AdjCtx
adjuvant chemoradiotherapy
- AHRQ
Agency for Healthcare Research and Quality
- ASCO
American Society of Clinical Oncology
- ASTRO
American Society of Therapeutic Radiation Oncology
- AUD
auditory acuity
- BON
bone
- BOT
base of tongue
- BRA
brachytherapy
- BRN
brain AEs
- BST
boost dose
- CCRTx
concurrent chemoradiotherapy
- CER
comparative effectiveness review
- CHT
chemotherapy only
- CNT
central nervous system tumor (including spine)
- CRN
cranial nerve tumors
- CRT
chemoradiotherapy
- CT
computed tomography
- CTP
cytoprotective agent
- CTV
clinical target volume
- CUT
cutaneous tumors (melanoma, etc.)
- def
definitive
- DFR
definitive RT
- DFS
disease-free survival
- DNT
dental AEs
- DS?
disease unclear
- DSS
(cancer) disease-specific survival
- DYS
dysphagia
- Dx
diagnosis
- EAR
ear tumors
- EORTC
European Organization for Research and Treatment of Cancer
- EPC
Evidence-based Practice Center
- EPICOT
Evidence, Population, Intervention, Comparators, Outcome, Time stamp
- ESO
esophagus AEs
- EST
esophageal or precursors
- ETH
ethmoid sinus
- EYE
eye tumors
- F/U
followup
- F/U?
followup uncertain
- freq
frequency
- Gr
grade
- grnd
ground
- GTV
gross tumor volume
- Gy
Gray
- Hb
hemoglobin
- HEM
hematologic tumor (including lymphoma
- HN
head and neck
- HNCI
Head and Neck Cancer Inventory
- HNQOL
Head and Neck Cancer-Specific Quality of Life
- HNU
head & neck unspecified
- HPV
human papillomavirus
- HRT
heart AEs
- HYF
hyperfractionation
- HYP
hypopharyngeal
- ICBT
intracavitary brachytherapy
- IMM
with immobilization
- IMR
IMRT
- IMRT
intensity modulated radiotherapy
- ITT
intention to treat
- LAR
laryngeal
- LC
local control
- LDH
lactate dehydrogenase
- LFF
local failure free
- LFFR
local freedom from recurrence
- LN
lymph node
- LNG
lung AEs
- LR
locoregional
- LRC
locoregional control
- LRPFS
locoregional progression-free survival
- LRRFS
locoregional recurrence-free survival
- LX
larynx AEs
- MAX
maxillary sinus
- MET
metastatic
- mets
metastases
- MFS
(distant) metastasis-free survival
- MIX
mixed head and neck
- MLT
major late toxicities
- mod
moderate
- mo(s).
month(s)
- MUC
mucous membrane AEs
- MVA
multivariable analysis
- NA
not applicable
- NBT
neutron beam therapy
- NCCN
National Comprehensive Cancer Network
- NCI CTC
National Cancer Institute’s Common Toxicity Criteria
- NeoadjCtx
neoadjuvant chemoradiotherapy
- NPC
nasopharyngeal cancer
- NPH
nasopharyngeal
- NR
not reported
- NRD
not relevant disease
- NRO
not relevant outcome (or no follow-up)
- NRT
not relevant treatment
- NS
not significant
- NV
nausea/vomiting
- O?
outcome unclear
- OAE
other AE
- OCL
oral cavity/lip
- OCU
ocular AEs
- OHN
other head and neck tumor
- OLF
olfactory AEs
- OPH
oropharyngeal
- ORN
osteoradionecrosis
- OS
overall survival
- OST
other non-head and neck solid tumor
- OTE
other time-to-event outcome
- OTO
otologic/auditory AEs
- PAL
palliative
- PAR
paraganglioma
- PBT
proton beam therapy
- PCR
postoperative CRT
- pctg
percentage
- PDQ
Physician Data Query
- PFS
progression-free survival
- PHR
pharyngeal
- PHX
pharynx
- PNS
paranasal sinus/nasal cavity
- postop
postoperative
- postopRT
postoperative radiotherapy
- postRT
after radiotherapy
- PRE
preoperative (neoadjuvant)
- preop
preoperative
- preopRT
preoperative radiotherapy
- preRT
before radiotherapy
- Pro
prospective
- prob(s)
probability(ies)
- PS
performance status
- PST
postoperative (adjuvant)
- PTH
parathyroid
- PTV
planning target volume
- Q#?
unclear if relevant to any key question
- QLQ
Quality of Life Questionnaire
- QOL
quality of life
- RCT
randomized, controlled trial
- REC
recurrent (reirradiation)
- ReRT
reirradiation
- Retro
retrospective
- RSE
radiosensitizing agent
- RSP
tumor response
- RT
radiotherapy
- RTOG
Radiation Therapy Oncology Group
- SAL
salivary gland, including parotid
- SB
skull base tumors
- SCC
small cell cancer
- sev
severity
- SF-36
Short Form-36
- SIN
sinus unspecified
- SKN
skin AEs
- SLF
salivary flow
- SOMA
Subjective, Objective, Management, Analytic
- SPN
spinal cord AEs
- SRS
stereotactic radiosurgery
- SRT
stereotactic radiotherapy
- SUB
subcutaneous tissue AEs
- SUR
surgery only
- Sx
symptoms
- T?
treatment unclear
- TAE
toxicity/adverse events (not specified)
- TEP
Technical Expert Panel
- THY
thyroid
- TR
tracheal tumors
- TRD
treatment-related death
- TTR
time-to-recurrence
- Tx
treatment
- UA
univariate analysis
- UCF
unspecified conformal RT
- UNP
unknown/occult primary
- URT
unspecified radiotherapy
- USPSTF
U.S. Preventive Services Task Force
- UWQOL
University of Washington Quality of Life
- VAS
visual analog scale
- VSA
visual acuity
- XQ
xerostomia questionnaire
- XST
xerostomia
- yr(s)
years
- Abbreviations - Comparative Effectiveness and Safety of Radiotherapy Treatments ...Abbreviations - Comparative Effectiveness and Safety of Radiotherapy Treatments for Head and Neck Cancer
Your browsing activity is empty.
Activity recording is turned off.
See more...